EHP exits SCA Pharma

Enhanced Healthcare Partners has exited its investment in SCA Pharmaceuticals as a result of the latter’s sale to The Vistria Group and Excellere Capital Management. No financial terms were disclosed. Based in Little Rock, Arkansas and Windsor, Connecticut, SCA Pharma is a provider of sterile admixtures and pre-filled syringes.

PRESS RELEASE

NEW YORK, NY (January 21, 2021) — Enhanced Healthcare Partners (“EHP”), a leading healthcare-focused private equity firm, is pleased to announce the successful exit from its platform investment in SCA Pharmaceuticals, LLC (“SCA Pharma”) through the sale of the business to The Vistria Group and Excellere Capital Management.

A leading FDA 503(B) outsourcing facility, SCA Pharma delivers the highest quality sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. With facilities in Little Rock, AR and Windsor, CT, SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns. Over the past five years, the Company has deeply invested in facility expansion, infrastructure, automation and quality to support the Company’s growth.

SCA Pharma’s CEO Milton Boyer said, “We are very pleased that as we continue our expansion efforts and improvements in our efficiencies, our new partnership with The Vistria Group and Excellere will allow us to accelerate these efforts. Both partners recognize the unprecedented growth that we have achieved and are committed to fast-tracking our expansion and automation goals.”

In speaking about its partnership with EHP, he continued, “We benefitted tremendously from our relationship with Enhanced and are grateful for their insight and support,” Boyer said. “Our growth under their leadership has been phenomenal.”

“We are proud of what SCA and the team accomplished throughout our partnership and are honored to have played a role assisting the company in its expansion and growth initiatives,” said EHP’s General Partner Matt Thompson. “We wish Milton—and the rest of the management team—the best of luck in this next stage of growth and could not be more confident in SCA’s ability to continue on its trajectory of growth and innovation.”

Terms of the transaction were not disclosed. William Blair & Company served as exclusive financial advisor and McDermott Will & Emery served as legal counsel to SCA Pharma.